Welcome to our dedicated page for Tarsus Pharmaceuticals news (Ticker: TARS), a resource for investors and traders seeking the latest updates and insights on Tarsus Pharmaceuticals stock.
Tarsus Pharmaceuticals, Inc. reports developments tied to its commercial eye-care franchise and biopharmaceutical pipeline. Company news commonly covers XDEMVY, its lotilaner ophthalmic solution marketed in the U.S. for Demodex blepharitis, including product-sales updates, prescribing trends, conference presentations, and international regulatory milestones for TP-03 through its Greater China partner.
Updates also address pipeline programs such as TP-04 for ocular rosacea and TP-05, an investigational oral lotilaner tablet being studied for Lyme disease prevention. Recurring corporate items include quarterly and annual financial results, investor-conference participation, board and governance changes, and business updates related to Tarsus' ophthalmology-focused commercialization strategy.
Tarsus Pharmaceuticals (NASDAQ: TARS) announced progress on its TP-03 development, a treatment for Demodex blepharitis. Following a productive FDA Type C meeting on December 8, Tarsus clarified NDA submission requirements and plans to initiate the Saturn-2 pivotal trial in 2021. TP-03 has shown promising results in previous trials, potentially positioning it as the first FDA-approved therapeutic for Demodex blepharitis, affecting over 9 million patients in the U.S.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) has been added to the Russell 3000® and Russell 2000® Indexes as part of the quarterly IPO additions. This membership, effective for one year, positions TARS for potential inclusion in the large-cap Russell 1000® Index as well as appropriate style indexes. Russell indexes are utilized by investment managers and institutional investors for managing approximately $9 trillion in assets. Tarsus is a late-stage biopharmaceutical firm focused on groundbreaking treatments, particularly in eye care, and is advancing its lead candidate for Demodex blepharitis.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) appointed Wendy L. Yarno to its Board of Directors and audit committee, enhancing its leadership team. With over 30 years of experience in biopharmaceuticals, including a significant tenure at Merck, Yarno's expertise in commercialization and management is expected to support Tarsus as it approaches the potential commercialization of its lead product, TP-03, aimed at treating Demodex blepharitis. Tarsus focuses on delivering breakthrough treatments for poorly treated diseases, particularly in eye care.
IRVINE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals (NASDAQ: TARS) announced that CEO Bobak Azamian will present at the Jefferies Virtual London Healthcare Conference on November 19, 2020, at 11:10 AM GMT. The webcast will be available for replay for 90 days. Tarsus is focused on breakthrough treatments for poorly treated diseases, starting with eye care. Its lead candidate, TP-03, is in Phase 2b/3 for treating Demodex blepharitis. Investor meetings will also take place during the conference.
Tarsus Pharmaceuticals, a late-stage biopharmaceutical company, has successfully completed its initial public offering, closing the sale of 6,325,000 shares at $16.00 each, raising approximately $101.2 million. The offering included 825,000 shares from the underwriters' additional option. Shares began trading on the Nasdaq Global Select Market under the ticker 'TARS' on October 16, 2020. Tarsus focuses on developing therapies for unmet needs in ophthalmology and other areas, with its lead candidate TP-03 in Phase 2b/3 trials for Demodex blepharitis.
Tarsus Pharmaceuticals has priced its initial public offering at $16.00 per share, aiming to raise approximately $88.0 million before expenses. The offering includes 5,500,000 shares, with an additional option for underwriters to purchase 825,000 shares. Trading of Tarsus’ common stock is set to commence on the Nasdaq Global Select Market under the symbol 'TARS' on October 16, 2020. The offering is anticipated to close around October 20, 2020, following standard closing conditions.